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Objective: To test the effectiveness and acceptability of an outpatient medical abortion protocol with 200 mg mifepristone and 400 mcg
sublingual misoprostol at 64–70 days' last menstrual period (LMP) and compare it to the already known efficacy of the 57–63 days' LMP
gestational age range.
Study Design: We conducted a prospective, comparative open-label trial in six hospitals and clinics in Ukraine, Georgia, India and Tunisia.
We enrolled 714 reproductive age women with pregnancies 57 to 70 days who presented requesting abortion. Medical abortions were
managed with the current service delivery protocol (200 mg oral mifepristone followed in 24–48 h by 400 mcg sublingual misoprostol).
Data on safety, efficacy and acceptability were collected. The main outcome measure was complete abortion without surgical intervention at
any point.
Results: A total of 703 cases were analyzable for efficacy. Success rates did not differ significantly in the two groups [57–63-day group:
94·8%; 64–70-day group: 91.9%; Relative Risk (RR): 0.79 (0.61–1.04)]. Ongoing pregnancy rates also did not differ significantly (57–63
days: 1.8%; 64–70 days: 2.2%; RR: 1.10 (0.65–1.87)].
Conclusion: A medical abortion regimen of 200 mg mifepristone followed in 24–48 h by 400 mcg sublingual misoprostol is effective
through 70 days' gestation and may be offered within existing outpatient abortion services.
Implications: A regimen of 200 mg mifepristone followed in 24–48 h by 400 mcg sublingual misoprostol is effective up to 70 days' LMP.
The findings have important implications for expanding access to outpatient medical abortion services in settings where the cost of
misoprostol is of concern or a two-pill misoprostol regimen is the standard of care.
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Mifepristone–misoprostol is used widely for early
abortion and recommended for outpatient use through 63
days from the last menstrual period (LMP) [1–3]. Earlier
studies demonstrated the effectiveness of medical abortion
after 9 weeks' LMP, but most protocols required repeat
dosing and inpatient care [4–10]. New evidence has shown
that the most common outpatient protocol for early medical
abortion in the United States (200 mg mifepristone followed
by 800 mcg buccal misoprostol) is effective and acceptable
for ending pregnancies 64–70 days from LMP and can be
offered without altering existing outpatient services [11].
The first regimens of medical abortion introduced in most
countries used 400 mcg oral misoprostol following mifepris-
tone for medical abortion through 49 days' gestation [12,13].
Evidence has since shown that medical abortion is also safe
and effective at increasing gestational ages, particularly using
other in-the-mouth routes (buccal and sublingual) or with
higher doses of misoprostol [1,14–18]. An alternative
outpatient protocol of 200 mg mifepristone followed by 400
mcg sublingual misoprostol is used through 63 days' LMP
[16,19] and is the standard of care in Tunisia, Georgia and
Moldova, among other countries that have historically used
two-pill misoprostol regimen since the method's introduction.
The higher-peakmisoprostol plasma concentration and greater
bioavailability associatedwith sublingual administration allow
for a lower dose of misoprostol when compared to buccal
administration [20]. Although generally an inexpensive drug,
the cost ofmisoprostol is subject to local market variability and
may be difficult to access or expensive in some settings. In
addition to a potentially reduced cost, lower doses of
misoprostol are associated with fewer side effects [19,21,22].
Our study sought to estimate the efficacy and acceptability of a
400-mcg sublingual misoprostol regimen following 200 mg
mifepristone through 70 days' LMP and to compare outcomes
betweenwomenwith pregnancies of 64–70 days' duration and
women with pregnancies in the range of 57–63 days.2. Materials and methods
This open-label prospective study was conducted be-
tween July 2009 and March 2012. Enrollment was planned at
seven facilities in four countries: Zhordania Institute of
Human Reproduction (Tbilisi, Georgia), Central District
Maternity House (Odessa, Ukraine); Maternity Hospital No.
2 (Simferopol, Ukraine); Naval Nursing Home (Solapur,
India); Government Medical College (Nagpur, India); La
Rabta Maternity Hospital (Tunis, Tunisia); and Family
Planning Center of Nabeul (Nabeul, Tunisia). One site was
found to have an excessive amount of incomplete data and
unanswerable queries on primary outcome data. Enrollment
was discontinued, and none of the data from that site (n=60)
was included in the analysis. The protocol was approved bythe institutional review board at each facility. The study was
registered with ClinicalTrials.gov, NCT00997347.
Women seeking abortion services were screened for
eligibility and asked to participate in the study. Eligible
women were 18 years or older, in good health and assessed
to have a pregnancy greater than 56 days and less than 71
days from LMP based on the standard gestational age
assessment practice at each site (ultrasound and/or clinical
exam and history). Participants had to be willing and able to
sign consent forms and agree to comply with the study
procedures and visit schedule. All women gave informed
consent to participate.
On day 1, women received 200 mg oral mifepristone and
were given the option of administering 400 mcg sublingual
misoprostol either in the clinic or at home 24–48 h later.
Women were instructed to place two pills under the tongue
for 30 min and swallow any remaining fragments. Each
participant received analgesic medication and/or a prescrip-
tion for analgesia, antidiarrheal and antiemetics as per
individual clinic protocol. Women were also provided with a
daily home study card to record bleeding days, time and date
of misoprostol administration, and information on where to
call with questions or concerns.
Women were asked to return to the clinic 7–14 days after
mifepristone administration for follow-up to determine
abortion outcomes. Outcome was determined by clinical
assessment, including ultrasonography as needed. Women
with an ongoing pregnancy were offered a surgical
evacuation. Women with nonviable pregnancies (e.g., sac
or other evidence of conception, but no growth in the
gestation or cardiac activity on ultrasound) were given
treatment options per the clinic's standard protocol including
expectant management, an additional dose of misoprostol or
a surgical evacuation. A short semistructured interview was
conducted once the abortion was complete. Women were
asked about the incidence and severity of side effects, and
the acceptability of the overall process, side effects and
bleeding. If a participant failed to return to the clinic, the
assessment of abortion status and interview could be
conducted via phone. If a woman failed to return or contact
the clinic, study sites attempted to contact the woman three
times before she was considered lost to follow-up.
The primary purpose of the trial was to assure that an
outpatient medical abortion regimen could be used in
gestations 64–70 days from LMP and achieve a success
rate of at least 90%, which would characterize a clinically
acceptable regimen. Three hundred thirty-four women per
group were needed to detect a 5% or greater lower efficacy
than the hypothesized 95% success rate in the 57–63 days
group, based on previously published reports (α=0.05, 1−
β=0.8, using a one-tailed test) and would allow us to
estimate a success rate of 90% with a confidence interval
(CI) of ±3.2% [13,18]. Data were analyzed using SPSS 15.0.
An independent data and safety monitoring committee
reviewed the interim results for safety and efficacy after
50% of the data were available.
able 2
edical abortion outcome, n (%)a
57–63 days
(n=382)
64–70 days
(n=321)
RR
(95% CI)
uccess 362 (94.8) 295 (91.9) 0.79 (0.61–1.04)
ailureb 20 (5.2) 26 (8.1)
Ongoing pregnancy 7 (1.8) 7 (2.2) 1.10 (0.65–1.86)
Persistent nonviable
pregnancy/sac
5 (1.3) 3 (0.9) 0.82 (0.33–2.01)
Substantial debris
in uterusc
4 (1.0) 6 (1.9) 1.32 (0.79–2.21)
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surgical intervention at any point, regardless of the number
of misoprostol doses used. Secondary outcomes included
side effects and days of heavy bleeding. Acceptability data
will be presented in a separate publication. One tailed pb.05
was considered to indicate statistical significance. Fischer's
exact test was used to determine differences in proportions
and Student t-test to determine differences in means of
continuous variables. The analysis of the primary outcome
was intent to treat.Excessive/prolonged
bleeding
2 (0.5) 8 (2.5) 1.77 (1.29–2.44)
Woman's request 1 (0.3) 1 (0.3) 1.10 (0.27–4.40)
Other 1 (0.3) 1 (0.3) 1.10 (0.27–4.39)
ajor adverse events
Received blood
transfusion
1 (0.3) 1 (0.3) 1.10 (0.27–4.39)
Hospital admission 2 (0.5) 1 (0.3) 0.73 (0.15–3.62)
a Excludes women lost to follow-up (57–63 days: 5; 64–70 days: 4) and
omen who withdrew from the study (57–63 days: 2).
b Includes 2 women who did not take misoprostol (57–63 days: 1; 64–
0 days: 1) and 8 women who did not administer the misoprostol per
rotocol (57–63 days: 1; 64–70 days: 7).
c Substantial debris was subjectively defined and differed by local
ractice.3. Results
A total of 714 women were enrolled: 389 women in the
57–63 days group and 325 women in the 64–70 days group.
Gestational age was confirmed by ultrasound in approxi-
mately three-quarters of all cases [57–63 days: 72.2% (281/
389); 64–70 days: 77.5% (252/325); p=.12]. Five women in
the 57–63 day group and 4 women in the 64–70 day group
were lost to follow-up. In the 57–63 day group, 8.2% of
women (32/389) were followed up by phone compared to
6.7% of women in the later gestational age group (22/325).
Two women in the 57–63 days group discontinued
participation in the study on or before the follow-up visit.
The final efficacy analysis included 703 women: 382 in the
earlier gestational age group and 321 in the later gestational
age group. The sociodemographic characteristics (mean age,
parity, abortion history, level of education) of the two groups
were similar (Table 1).
The success rate was 94.8% (or 362/382) in the 57–63
days group and 91.9% (or 295/321) in the 64–70 days group
[Relative Risk (RR): 0.79 (0.61–1.04)] (Table 2). TwoTable 1
Participant characteristics
57–63 days
(n=389)
64–70 days
(n=325)
p-Valuea
Age (y), mean
(SD) (range)
27.7 (5.7) (18–46) 28.1 (6.4) (18–47) .36
Gravidityb .88
1 69 (17.7) 80 (18.5)
2 96 (24.7) 72 (22.2)
3 78 (20.1) 65 (20.0)
4+ 146 (37.5) 128 (39.4)
Previous abortionb 173 (44.5) 150 (46.2) .71
Previous medical
abortionb
68 (17.5) 55 (16.9) .92
Educationb .81
No formal education 11 (2.8) 8 (2.5)
Less than high school 47 (12.1) 48 (14.8)
High school 183 (47.0) 150 (46.2)
University
or postgraduate
147 (37.8) 117 (36.0)
Unknown 1 (0.3) 2 (0.6)
a Two-tailed p-value; Student t-test for difference in means; Fischer's
exact test for difference in proportions.
b Values are presented as n (%).T
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ppercent of women in each group received a surgical
evacuation for an ongoing pregnancy [57–63 days: 1.8%
(7/382); 64–70 days: 2.2% (7/321); RR: 1.10 (0.65–1.87)].
There was a significant difference between the two groups in
rates of surgical evacuation for excessive or prolonged
bleeding [57–63 days: 0.5% (2/382); 64–70 days: 2.5% (8/
321); RR: 1.77 (1.29–2.44)].
Almost all women took the misoprostol according to
protocol [57–63 days: 98.7% (384/389); 64–70 days: 97.5%
(317/325)]. Most women elected to take the misoprostol at
home [57–63 days: 78.9% (307/389); 64–70 days: 72.6%
(236/325); p=.05]. Significantly more women in the later
gestational group received one additional dose of 400 mcg
sublingual misoprostol at the follow-up visit for management
of bleeding or a retained sac [57–63 days: 5.7% (22/386);
64–70 days: 10.5% (34/325); p=.03].
Two women did not take the misoprostol at all (1 in 57–
63 days group and 1 in the 64–70 days group) and failed to
expel the ongoing pregnancy. Four women took misoprostol
more than 48 h after mifepristone administration (i.e., 72–74
h after mifepristone administration). Of these, three women
in the 64–70 days group had a successful medical abortion
and one woman in the 57–63 days group underwent a
surgical evacuation for a persistent nonviable sac.
Four women in the 64–70 days group used an alternate
route of misoprostol administration. One woman adminis-
tered the pills buccally and had a successful outcome. Three
women administered the tablets orally. Two had a successful
outcome, and one woman underwent a surgical evacuation
and was hospitalized and received a blood transfusion as
treatment for prolonged bleeding. A per-protocol analysis
excluding cases who failed to administer the misoprostol or
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or oral) or more than 48 h after mifepristone yields slightly
higher success rates, which were still not significantly
different [57–63 days: 95.0% (361/380); 64–70 days: 92.7%
(290/313); p=.21].
Three women in the study (including the protocol
violation mentioned above) were hospitalized due to
bleeding during the study period [57–63 days: 0.5% (2/
382); 64–70 days: 0.3% (1/321); RR: 0.73 (0.15–3.62)].
One woman in the earlier gestational age group and one
woman in the later gestational age group received a blood
transfusion (p=1.000).
Ultrasound was performed at the follow-up visit in
approximately two-thirds of cases [57–63 days: 61.1% (214/
350); 64–70 days: 67.9% (197/290); p=.08]. Among women
who returned to the clinic for follow-up, women in the later
gestational age group were assessed as incomplete (i.e.,
persistent gestational sac or substantial debris as diagnosed
by ultrasound) at the follow-up visit at a higher rate than
women in the earlier gestational age group [57–63 days:
6.5% (21/350); 64–70 days: 9.7% (29/298); RR: 1.29 (1.00–
1.66); p=.08]. Most women with incomplete expulsion were
treated with additional misoprostol [57–63 days: 52.3% (11/
21); 64–70 days: 75.9% (22/29); p=.13]. Of those women
who received an additional dose of misoprostol, most went
on to have a successful abortion [57–63 days: 90.9% (10/
11); 64–70 days: 86.3% (19/22); p=.35].
Self-reported side effects experienced by women in both
groups were similar. Over one-third of women in both
groups reported no side effects [57–63 days: 38.2% (145/
380); 64–70 days: 35.4% (111/314); RR: 1.07 (0.90–1.27)].
Reported rates of diarrhea, nausea, vomiting, chills,
headache, dizziness and weakness were not significantly
different in the two study groups (Table 3). Reports of fever
were slightly fewer in the lower gestational age group [57–
63 days: 9.2% (35/380); 64–70 days: 14.0% (44/314); RR:
0.79 (0.64–0.98)].Table 3
Side effects [n (%)]
57–63 days
(n=380)
64–70 days
(n=314)
RR
(95% CI)
None 145 (38.2) 111 (35.4) 1.07 (0.90–1.27)
Diarrhea 35 (9.2) 39 (12.4) 0.84 (0.67–1.06)
Nausea 139 (36.6) 118 (37.6) 0.98 (0.83–1.16)
Vomitinga 54 (14.2) 56 (17.9) 0.87 (0.71–1.06)
Fever 35 (9.2) 44 (14.0) 0.79 (0.64–0.98)
Chills 65 (17.1) 63 (20.1) 0.90 (0.74–1.10)
Headache 61 (16.1) 51 (16.2) 0.99 (0.80–1.24)
Dizziness 70 (18.4) 69 (22.0) 0.89 (0.73–1.08)
Weakness 133 (35.2) 121 (38.5) 0.92 (0.78–1.09)
Heavy bleeding n=350 n=302 p=.05
Days of heavy
bleeding
1.89±1.37 (0–9) 2.10±1.39 (0–7)
Median days of
heavy bleeding
2 2
a The 64–70 days group (n=313).Data on bleeding were collected on a diary completed at
home. Almost all women (93.2%, or 655/703) completed the
diary. The median duration of all bleeding (i.e., spotting,
moderate and heavy bleeding) was slightly longer in the later
gestational age group (57–63 days: 10 median days; 64–70
days: 11 median days), although the mean difference in
bleeding was not statistically significant (57–63 days: 9.8±
3.0; 64–70 days: 10.2±3.0; p=.07). The mean difference in
duration of heavy bleeding between the two groups
approached significance (p=.05), with women in the 64–70
days group reporting slightly more days of heavy bleeding
than their counterparts in the lower gestational age group
(Table 3).
Approximately half of women in both groups used
nonsteroidal anti-inflammatory drugs for pain management
[57–63 days: 47.6% (182/382); 64–70 days: 53.6% (172/
321); p=.13]. Rates of narcotic use were low and not
significantly different between groups [57–63 days: 18.3%
(70/382); 64–70 days: 17.8% (57/321); p=.92]. Mean days
of any pain medication was not significantly different
between the two study groups (57–63 days: 2.0 mean
days; 64–70 days: 2.2 mean days; p=.35).4. Discussion
Medical abortion with an outpatient regimen of 200 mg
mifepristone followed 24–48 h later by 400 mcg sublingual
misoprostol is effective in women 57 to 70 days from LMP.
Our results are consistent with other studies of outpatient
medical abortion regimens to 70 days' LMP [11,23].
Winikoff et al. [11] found a success rate of 92.8% (95%
CI: 89–95) with a regimen of 200 mg mifepristone and 800
mcg buccal misoprostol in women with gestational ages 64–
70 days from LMP. Rates of ongoing pregnancy in this
group were also consistent across studies; the rate of ongoing
pregnancy in this study (2.2%) was slightly lower than
reported rate in the study of the 800 mcg buccal regimen
(3.0%).
This study did show a statistically significant difference in
the rate of surgical intervention for excessive/prolonged
bleeding between the two study arms (0.5% in 57–63 days
vs. 2.5% in 64–70 days). The rate of intervention in the
higher gestational age group (2.5%) was also higher than the
reported rate for a regimen of 200 mg following in 24–48 h
by 800 mcg buccal misoprostol (1.0%, or 3/304) [11]. Most
interventions for prolonged bleeding (8/10) occurred at two
hospital study sites. The differences in rates of intervention
for management of bleeding may reflect variations in
provider practice for management of incomplete abortion.
Still, women in the 64–70 days group may have also
experienced slightly more bleeding. Women at the more
advanced gestational age group did report experiencing more
median days of bleeding (57–63 days: 10 median days; 64–
70 days: 11 median days). The difference in mean duration
of heavy bleeding between groups did approach significance
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p=.05) but was similar to the rate reported for the 800 mcg
buccal outpatient regimen (57–63 days: 2.5 mean days; 64–
70 days: 2.3 mean days) [11].
Only fever was significantly more likely to be reported by
women in the higher gestational age group. Relatively few
women reported this side effect (57–63 days: 9.2%; 64–70
days: 14.0%). The difference, while statistically significant,
may not be clinically relevant. The incidence of fever
reported in this study is slightly lower than prior studies of
this regimen (28.1% and 25.0%) [16,19]. Reports of chills
(57–63 days: 17.3% and 64–70 days: 20.1%) are also lower
than reports of chills/shivering from prior studies of 400- and
800-mcg regimens (38% and 52.9% of women reported
experiencing chills/shivering up to 3 h after misoprostol
administration, respectively) [21]. Fever and chills are
commonly reported side effects associated with sublingual
misoprostol administration, and the effect may be a result of
the higher misoprostol plasma concentrations after sublin-
gual administration [17,18].
This studywas not powered to detect a difference in adverse
events because these outcomes (e.g., hospitalization or need
for transfusion) are rare. This study also suggests that such
events occur infrequently with no evidence of a difference by
gestational age. The study was conducted in sites where
ultrasound is not used routinely for gestational age dating, but
gestational age was confirmed by ultrasound in over three-
quarters of cases in both groups. It is possible that some
women could have been misclassified into study groups based
on variability in woman's report of LMP or clinical
assessment. Even so, the findings may help to reassure
providers that medical abortion may be safely provided up to
the 70 days' LMP without relying exclusively on ultrasonog-
raphy for gestational age dating. Access to ultrasonography
may be limited in many places where improved access to first
trimester abortion services is greatly needed.
One limitation of the study is that the study was not
blinded and two categories of failure (excessive bleeding and
substantial debris in the uterus) are dependent upon
subjective evaluation. As indicated above, interventions for
excessive bleeding were primarily confined to two study
sites. Rates of intervention for substantial debris in the uterus
also varied with slightly higher rates in Tbilisi and Odessa
(2.2% and 2.3%) compared to the sites in India and Tunisia
(0–1%), where ultrasound use was less frequent.
In conclusion, the study findings show that a regimen of
200 mg mifepristone followed in 24–48 h by sublingual
misoprostol is effective. The study results demonstrate that it is
possible to expand access to outpatient regimens to 70 days'
LMP using mifepristone plus a two-pill misoprostol regimen.
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